Kiora Pharmaceuticals, Inc. Common Stock
$2.76
$0.09 (+3.37%)
$2.63Day Range$2.85
Key Statistics
Market Cap
$12.21M
Shares Outstanding
4.4M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Feb 13, 2015
Round Lot
100
Locale
US
Trading Data
Day Open
$2.63
Day High
$2.85
Day Low
$2.63
Volume
50.0K
VWAP
$2.75
Prev Close
$2.67
Transactions
--
Acc. Volume
--
About Kiora Pharmaceuticals, Inc. Common Stock
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
PHARMACEUTICAL PREPARATIONSSIC 283413 employees169 SAXONY RD., ENCINITAS, CA, 92024858-224-9600IPO Feb 13, 2015US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001372514
- Composite FIGI
- BBG0083Y1PH9
- Share Class FIGI
- BBG0083Y1Q78
- Ticker Root
- KPRX
- SIC Code
- 2834
About Kiora Pharmaceuticals, Inc. Common Stock (KPRX) Stock
Kiora Pharmaceuticals, Inc. Common Stock (KPRX) closed the 2026-09-18 session at $2.76, up 3.37% versus the previous close (+0.09). The stock opened at $2.63 and traded between $2.63 and $2.85 during that session. Session trading volume was 50K shares. The volume-weighted average price (VWAP) is $2.75.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
Kiora Pharmaceuticals, Inc. Common Stock has a market capitalization of $12.2 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. KPRX is listed on the XNAS exchange. The company employs approximately 13 people. Kiora Pharmaceuticals, Inc. Common Stock is headquartered in ENCINITAS, CA. The recorded listing date is 2015-02-13.
On this page you can find market KPRX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.